(Credit-Canva)
The current measles outbreak has gripped US states like Texas and New Mexico leaving people worried whether it would become a new pandemic. According to the Texas Department of State Health Services as of February 21, 90 cases were diagnosed in the last month in the South Plains area, with at least 77 of them were reported in children and teens under 17.
Measles is highly contagious and can be deadly. The outbreak, which started spreading in late January, has resulted in multiple hospitalizations, with at least nine confirmed cases and three probable cases as of early February. Health officials caution that at least one in five infected individuals will have to be hospitalized, highlighting the severity of the situation.
Misinformation surrounding vaccines and with the new Trump administration anti-vaccine campaigs, has causing parents to hesitate or refuse vaccination.
Furthermore, the country down under Australia is also witnessing a surge in measles cases as health officials in Sydney have issued an urgent alert, urging residents to watch for measles symptoms after an infected individual visited several places in Sydney over the last seven days.
Authorities report that the traveller had returned from South East Asia where there are ongoing outbreaks of measles.
Key symptoms of measles include fever, a runny nose, sore eyes, and a cough. Typically, a red, blotchy rash appears three to four days later, spreading from the head down to the body. Symptoms can manifest between 7 and 18 days after exposure.
Anyone who experiences these symptoms after potential exposure should immediately contact their doctor or emergency department. It is crucial to call ahead before visiting to avoid potentially exposing others in the waiting room. Dr. Selvey also highlighted that ongoing measles outbreaks are occurring in various parts of the world, making awareness and prompt action essential.
According to CDC everyone should get the MMR vaccine. It protects you from measles, mumps, and rubella. Getting vaccinated helps stop these diseases from spreading. There are two safe MMR vaccines available. They work the same way, so it doesn't matter which one you get. Kids can also get a shot that protects against chickenpox too, but this is only for children.
All children should get two MMR shots. The first shot should be given when they are between 12 and 15 months old. The second shot should be given when they are between 4 and 6 years old. If needed, the second shot can be given earlier, but it must be at least 28 days after the first shot.
Students going to college or other schools after high school, need two shots if they are not already immune. The shots must be at least 28 days apart.
Most adults need at least one MMR shot. Some adults need two shots, especially those who work in healthcare, travel a lot, or go to college. These people should get two shots, with 28 days between them.
Anyone traveling to other countries should make sure they are protected. Babies 6 to 11 months old should get one shot before traveling. Kids 12 months and older, teens, and adults need two shots, with 28 days between them.
People who work in healthcare should have proof that they are immune to measles, mumps, and rubella. If they are not immune, they need two MMR shots, spaced 28 days apart.
Women who might get pregnant should talk to their doctor about the MMR vaccine. It's safe to get the shot while breastfeeding.
Credit: iStock
Long associated with factors such as obesity, lifestyle and genetics, cancer can also be linked to infections. A new study published in The Lancet Oncology found that an estimated 2.3 million new cancer cases globally in 2024 — 12%, or about one in eight of all cancers diagnosed that year — were attributable to infections.
The analysis included 12 infectious agents known to cause cancer in humans, including viruses, a bacterium and parasites. It also incorporated newly established infection-cancer associations and additional cancer types caused by known carcinogenic infections, including recent evidence linking Epstein-Barr virus (EBV) with gastric cancer.
“The findings underscore the major role that infection control can play in reducing the global cancer burden,” said Dr Harriet Rumgay, a scientist in the Cancer Surveillance Branch at IARC.
“Despite progress in vaccination and screening, infection-related cancers remain a major global challenge, with the burden falling disproportionately on populations in low- and middle-income countries,” Rumgay added.
Also read: US Cancer Death Rates Fall For Men, Women: Lung Cancer Progress Drives Decline
Based on cancer burden estimates from the IARC Global Cancer Observatory database, the researchers assessed 12 infectious agents known to cause cancer: Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), EBV, Kaposi sarcoma-associated herpesvirus (KSHV), Schistosoma haematobium, human T-cell lymphotropic virus type 1 (HTLV-1), Opisthorchis viverrini, Clonorchis sinensis, Merkel cell polyomavirus and HIV.
Five of these accounted for almost all infection-linked cancer cases in 2024:
Low- and middle-income countries accounted for 77% of all infection-linked cancer cases.
Eastern Asia recorded the largest number of infection-attributable cancer cases, with 990,000 cases — 42% of the global total — driven mainly by H. pylori and HBV.
Sub-Saharan Africa had the highest proportion of cancers linked to infection, with a quarter of all cancers in the region attributed to infectious agents. The burden was driven largely by HPV, KSHV and HIV.
The study also found that EBV is the fourth-largest infectious cause of cancer globally, ahead of HCV. This reflects growing evidence that EBV contributes not only to nasopharyngeal cancer and lymphomas but also to a proportion of gastric cancers.
Read More: Fatty Liver, Chronic Gut Diseases And Worm Infections: India’s Changing Disease Burden
The authors said the findings underline the importance of infection control in reducing cancer rates. They highlighted several measures that are already available but remain underused, including
Many of these measures are cost-effective but remain underused in many countries because of societal, financial and political barriers.
“This updated analysis shows that the landscape of infection-related cancers continues to evolve as scientific evidence advances,” said Dr Gary Clifford, senior co-author of the study.
“It also highlights where future investments in new prevention tools could have the greatest impact, particularly for infections such as EBV, for which effective vaccines are not yet available.”
The authors said reducing infection-related cancers will require wider implementation of established prevention strategies, alongside continued investment in new tools, particularly vaccines against EBV and other cancer-causing infections for which effective preventive measures are not yet available.
Credit: iStock
India is among 20 jurisdictions whose qualifying specialty pharmaceutical products and related ingredients can receive a zero per cent US tariff, according to a new notice from the US Commerce Department.
The exemption comes as the US begins applying a 100 per cent tariff on certain patented pharmaceutical products and associated ingredients from September 29.
The tariff measures stem from a presidential proclamation issued in April under Section 232 of the Trade Expansion Act, which sought to address US dependence on imported pharmaceuticals and encourage greater domestic production.
Also read: US FDA Recalls India-Made BP Drug For The Second Time In 3 Months: Here's Why
The waiver applies to specific pharmaceutical categories rather than the wider drug trade.
Products covered by the notice include:
The provision also covers qualifying ingredients associated with these products.
The Commerce Department said products from the listed jurisdictions can receive the zero tariff because those jurisdictions have a current or forthcoming trade and security framework agreement with the US.
The exemption therefore applies based on both the type of pharmaceutical product and the applicable country-level conditions.
The move comes against the backdrop of the US administration's broader effort to increase domestic pharmaceutical production and reduce reliance on imported medicines and pharmaceutical ingredients.
The 100 per cent tariff on specified patented pharmaceutical products and ingredients began applying to companies identified in one category from July 31, while the measure extends to additional covered companies from September 29.
The Commerce Department notice also makes clear that generic pharmaceutical products, biosimilars and their associated ingredients are not currently subject to the Section 232 pharmaceutical tariffs.
This means the latest exemption should not be interpreted as a broad tariff concession covering India's entire pharmaceutical industry.
The guidance also makes technical changes to the Harmonized Tariff Schedule and clarifies the treatment and definitions of pharmaceutical articles and generic pharmaceutical products under the tariff framework.
Companies seeking an exemption on the basis of an urgent US health need can apply through a process established by the Commerce Department.
India's inclusion in the zero-tariff category is relevant to pharmaceutical companies that export specialty medicines and their associated ingredients to the US.
However, the exemption is not a blanket waiver for medicines manufactured or exported from India.
Only products that fall within the specified categories and satisfy the applicable conditions are covered. Other pharmaceutical products remain subject to the tariff rules that apply to them.
For Indian drug makers, the distinction is important because the new provision specifically concerns specialty pharmaceutical categories, while generic medicines and biosimilars are already outside the current Section 232 pharmaceutical tariffs.
The impact on individual Indian pharmaceutical companies will therefore depend on the types of products they export to the US and whether those products meet the criteria set out under the new rules.
Besides India, the zero-tariff category covers Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland, Liechtenstein, Taiwan, Thailand, the UK and Vietnam.
(With inputs from PTI)
Credit: iStock
Pennsylvania has recorded 903 measles cases, while the US national tally has climbed to 3,659.
Pennsylvania, which is among the worst-hit states in the ongoing outbreak, added 115 cases in the past week, according to the state Department of Health.
The Centers for Disease Control and Prevention (CDC) has also listed Pennsylvania among the states reporting the highest number of measles cases, followed by South Carolina and Utah.
Pennsylvania has reported four deaths so far due to measles, although the CDC has acknowledged only two.
Two of the deaths were among unvaccinated adults — an 18-year-old and a 40-year-old. The other two deaths were among infants who were too young to have received the measles, mumps, rubella (MMR) vaccine.
According to Pennsylvania’s health department, less than 1% of measles cases occurred in people who were fully vaccinated against the virus. A total of 176 people have been hospitalized, while about 31% of cases occurred in people under 18.
This year has been one of the worst for measles in the US in more than 30 years, with the highest number of annual cases reported since 1992.
The US eliminated measles in 2000, but that status is set to be reevaluated at an upcoming November meeting with the Pan American Health Organization. Canada lost its measles elimination status last year.
As per the CDC, 3,659 confirmed measles cases were reported in the US through September 24. In comparison, a total of 2,289 confirmed measles cases were reported in the US during the full year of 2025.
About 95% of cases were among people who were unvaccinated or whose vaccination status was unknown. Around 9% of cases resulted in hospitalization, while 14% occurred among children under five.
Measles Cases By Age
Other states have also reported increases in measles cases.
Ohio added nine new cases this week and now has 189 cases for the year. Kentucky added 10 new cases and has 67 for the year, while Wisconsin added four new cases and has reported 171 cases so far this year.
Read More: Bill Gates Says Vaccine Hesitancy Could Make Ending Measles Impossible
Commenting on the measles resurgence, Dr Saia Ma’u Piukala, Regional Director for the Western Pacific, said the world risks “bringing back a disease we have long known how to prevent”.
Piukala lamented the loss of years of progress in measles vaccination and attributed the resurgence to vaccination challenges during the COVID-19 pandemic, coupled with mounting anti-vaccine misinformation.
“Behind every outbreak is a gap: a missed child, delayed action, weakened trust or communities not reached through regular vaccination programs. In the Western Pacific – home to 2.2 billion people, more than a quarter of the world’s population – an immunity gap in one country quickly becomes a regional risk,” he said.
“This should concern all of us because measles is not only about one disease. It is one of the clearest signals of whether health systems are strong, consistent and serving everyone.”
Measles cases are also being reported in Bangladesh and India. Bangladesh, Guatemala, India and Yemen currently have some of the highest reported case counts.
India has reported 26,627 measles cases in the first half of 2026, making it the world’s second-highest tally. Recently, the country also reported two measles deaths in Kerala's Malappuram.
Bangladesh has reported 189,255 suspected measles cases nationwide since March. Confirmed and suspected measles-related deaths in Bangladesh have reportedly reached 1,099 this year.
© $2026 Times Horizon Private Limited